StockNews.com Begins Coverage on Aeterna Zentaris (NASDAQ:AEZS)

Research analysts at StockNews.com started coverage on shares of Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) in a research note issued to investors on Thursday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Aeterna Zentaris Trading Up 3.2 %

NASDAQ AEZS opened at $2.67 on Thursday. The company has a market capitalization of $4.79 million, a PE ratio of -0.18 and a beta of 1.55. Aeterna Zentaris has a 12 month low of $3.96 and a 12 month high of $12.00. The stock has a 50-day simple moving average of $3.21 and a 200 day simple moving average of $4.36.

About Aeterna Zentaris

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis.